甲磺酸阿帕替尼片治疗Ⅲ、Ⅳ期非小细胞肺癌的近期疗效

Short term efficacy of apatinib mesylate tablets in the treatment of stage Ⅲ and Ⅳ non-small cell lung cancer

目的甲磺酸阿帕替尼片治疗Ⅲ、Ⅳ期非小细胞肺癌的近期疗效。方法 120例Ⅲ、Ⅳ期非小细胞肺癌患者,随机分为对照组和研究组,每组60例。对照组患者采用常规治疗,研究组患者在对照组基础上采用甲磺酸阿帕替尼片治疗。比较两组患者的治疗效果及不良反应发生情况。结果研究组患者不良反应发生率为56.7%,显著低于对照组的80.0%,差异具有统计学意义(P<0.05)。研究组患者治疗总有效率为65.0%,显著高于对照组的23.3%,差异具有统计学意义(P<0.05)。结论在Ⅲ、Ⅳ期非小细胞肺癌治疗过程中,甲磺酸阿帕替尼片可以较快地减少不良反应的发生,有效控制癌细胞的扩散,治疗效果理想,临床上值得进一步推广应用。

Objective To discuss the short term efficacy of apatinib mesylate tablets in the treatment of stage Ⅲ and Ⅳ non-small cell lung cancer.Methods A total of 120 patients with stage Ⅲ and Ⅳ non-small cell lung cancer were randomly divided into control group and research group,with 60 cases in each group.The control group received conventional therapy,and the research group received apatinib mesylate tablets on the basis of the control group.The treatment effect and occurrence of adverse reactions between the two groups was compared.Results The research group had significantly lower incidence of adverse reactions as 56.7%than 80.0%in the control group,and the difference was statistically significant(P<0.05).The research group had significantly higher total treatment effective rate as 65.0%than 23.3%in the control group,and the difference was statistically significant(P<0.05).Conclusion During the treatment of stageⅢandⅣnon-small cell lung cancer,apatinib mesylate tablets can quickly reduce the occurrence of adverse reactions,effectively control the spread of cancer cells with ideal treatment effect.It is worth further clinical promotion and application.